SEATTLE, March 5 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals,
Inc. (Nasdaq: TRBN), today announced that executives will present an
overview of the company at two March investor conferences:
-- March 10: Sanford Bernstein Biotechnology Conference in Alta, Utah. Dr.
Peter Thompson, president, CEO and chairman, will present to attendees.
-- March 18: Invest Northwest CEO & Investor Forum at the Bell Harbor
International Conference Center, 2211 Alaskan Way, Pier 66 in Seattle,
Wash. Dr. Ken Mohler, co-founder and senior vice president of Research
and Development, is scheduled to present at 11:20 a.m. PDT. The
presentation will be available via audio webcast at
Trubion is a biopharmaceutical company that is creating a pipeline of novel protein therapeutic product candidates to treat autoimmune and inflammatory diseases and cancer. The company's mission is to develop a variety of first-in-class and best-in-class product candidates, customized for optimal safety, efficacy, and convenience that it believes may offer improved patient experiences. Trubion's current product candidates are novel single-chain polypeptide protein, or SMIPtm, therapeutics, and are designed using its custom drug assembly technology. Trubion's lead product candidate, TRU-015, has completed a Phase 2b clinical trial for the treatment of rheumatoid arthritis, and is also in development under the Wyeth collaboration for the treatment of non-Hodgkin's lymphoma, Systemic Lupus Erythematosus and other undisclosed indications.
Trubion's proprietary product candidat
|SOURCE Trubion Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved